YS Biopharma Co., Ltd. reported earnings results for the nine months ended December 31, 2023. For the nine months, the company reported sales was CNY 0.438069 million compared to CNY 0.581184 million a year ago. Net loss was CNY 0.252293 million compared to CNY 0.172506 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9857 USD | +0.80% | +8.49% | +91.10% |
04-19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
04-18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.10% | 184M | |
-3.05% | 90.45B | |
+3.95% | 41.45B | |
-10.82% | 33.57B | |
+60.58% | 25.73B | |
-20.72% | 14.73B | |
-9.01% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- YS Stock
- News YS Biopharma Co., Ltd.
- YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023